Hallac A, et al. - Via a prospectively maintained institutional pancreatic resection database, 324 subjects who underwent distal pancreatectomy from 2005 to 2015 were recognized by the researchers in order to define the prevalence of exocrine pancreatic insufficiency (EPI) in such subjects and furthermore recognize risk factors for developing de-novo EPI following distal pancreatectomy. New-onset EPI needing pancreatic enzyme replacement therapy was noted in 38 subjects. No association between patient demographics or diabetes status and the requirement for pancreatic enzyme replacement therapy and no important impact of resection volume on the necessity for pancreatic enzyme replacement therapy post-operatively was noted. The development of de-novo EPI was significantly prognosticated by having an underlying obstructive pancreatic pathology or a presenting history of acute pancreatitis. Hence, pre-existing EPI at the time of surgery was not unusual. Moreover, for the requirement for pancreatic enzyme replacement therapy, subjects exhibiting for distal pancreatectomy should be evaluated preoperatively.